Investor Relations

Recent Event

H.C. Wainwright Global Investment Conference

Company Overview

 BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Investor Contact Information

Company

BiomX, Inc.
22 Einstein St.
Floor 5
Ness Ziona 7414003
Israel
info@biomx.com

Investor Relations

Anat Primovich
Corporate Project Manager
T: +972506977228
anatp@biomx.com

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.